AMARIN CORP PLC\UK Investment Income, Interest
AMARIN CORP PLC\UK (AMRN) reported Investment Income, Interest of $3.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-07-29
- AMARIN CORP PLC\UK investment income, interest for the quarter ending 2026-06-30 was $3.05M, a 16.41% increase year-over-year.
- AMARIN CORP PLC\UK investment income, interest for the quarter ending 2026-03-31 was $2.42M, a 15.63% decline year-over-year.
- AMARIN CORP PLC\UK investment income, interest for the quarter ending 2025-06-30 was $2.62M.
- AMARIN CORP PLC\UK investment income, interest for the quarter ending 2025-03-31 was $2.87M.
- AMARIN CORP PLC\UK investment income, interest for fiscal 2025 was $10.85M, a 19.03% decline from fiscal 2024.
- AMARIN CORP PLC\UK investment income, interest for fiscal 2024 was $13.40M, a 12.98% increase from fiscal 2023.
- AMARIN CORP PLC\UK investment income, interest for fiscal 2023 was $11.86M, a 320.82% increase from fiscal 2022.
- AMARIN CORP PLC\UK investment income, interest for fiscal 2022 was $2.82M, a 131.07% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 12 month |
|---|---|---|---|
| 2026-06-30 | $3.05M 10-Q · filed 2026-07-29 | $5.47M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $2.42M 10-Q · filed 2026-04-29 | ||
| 2025-12-31 | $10.85M 10-K · filed 2026-03-02 | ||
| 2025-06-30 | $2.62M 10-Q · filed 2026-07-29 | $5.49M 10-Q · filed 2026-07-29 | |
| 2025-03-31 | $2.87M 10-Q · filed 2026-04-29 | ||
| 2024-12-31 | $13.40M 10-K · filed 2026-03-02 | ||
| 2023-12-31 | $11.86M 10-K · filed 2026-03-02 | ||
| 2022-12-31 | $2.82M 10-K · filed 2025-03-12 | ||
| 2021-12-31 | $1.22M 10-K · filed 2024-02-29 | ||
| 2020-12-31 | $4.90M 10-K · filed 2023-03-01 | ||
| 2019-12-31 | $8.50M 10-K · filed 2022-03-01 | ||
| 2018-12-31 | $1.07M 10-K · filed 2021-02-25 | ||
| 2017-12-31 | $429.00K 10-K · filed 2020-02-25 | ||
| 2016-12-31 | $234.00K 10-K · filed 2019-02-27 | ||
| 2015-12-31 | $132.00K 10-K · filed 2018-02-27 | ||
| 2014-12-31 | $96.00K 10-K · filed 2017-03-01 | ||
| 2013-12-31 | $343.00K 10-K · filed 2016-02-25 | ||
| 2012-12-31 | $544.00K 10-K · filed 2015-03-03 | ||
| 2011-12-31 | $231.00K 10-K · filed 2014-02-27 | ||
| 2010-12-31 | $53.00K 10-K · filed 2013-02-28 | ||
| 2009-12-31 | $199.00K 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B |